Business Wire

MA-PTC

1.7.2020 22:02:08 CEST | Business Wire | Press release

Share
Inaugural Virtual Edition of LiveWorx Digital Transformation Event Draws Thousands

For the first time in the event’s decade-long history, the annual LiveWorx® digital transformation event took place online, uniting tens of thousands of industry leaders across the world. Chaired by presenting sponsor, PTC (NASDAQ: PTC), the one-day event featured more than 120 sessions spanning topics ranging from Augmented Reality (AR) , Artificial Intelligence (AI), 5G, Robotics, Software as a Service (SaaS) , Industrial Internet of Things (IIoT) , Product Lifecycle Management (PLM) , and Computer-Aided Design (CAD) , and more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005892/en/

“This year’s virtual event brought to life the magic, excitement, and drive for transformative change that we all experience at the annual in-person version,” said Jim Heppelmann, President and CEO, PTC. “I was particularly pleased to see the force of change magnified inside and outside of this year’s event. For the global society, 2020 has been a year of challenge and growth. I look forward to seeing how this year’s energy and drive will be matched in next year’s event.”

Energizing Change

In support of movements and causes that shape the world in which the technology community operates, the LiveWorx event recognized four charities as beneficiaries for donations stemming from attendee actions throughout the event. For each attendee who entered the virtual Networking Lounge, shared their experience on social media using #LiveWorx, or completed an online scavenger hunt, approximately $1 per action was donated to charities including WWF - World Wildlife Fund , International Rescue Committee , Save the Children , and Black Girls CODE . Following the event’s final keynote session, all donations were matched by presenting sponsor, PTC.

“Bringing to life the Black Girls CODE story during this year’s LiveWorx event enabled us to raise awareness of our mission across the globe, and reinforce why we need to confront this crisis today to ensure a brighter and more inclusive tomorrow,” said Kimberly Bryant, Founder and CEO, Black Girls CODE. “While there is still a lot of work to do, I am proud to have had the opportunity to share this message, and will continue to champion inclusion for all of the women entering the STEM community.”

As part of its mission to foster inclusion across the technology industry, LiveWorx continuously endeavors to reflect more gender, racial, and geographic diversity in STEM fields represented at the event. At this year’s event, 21% of presenters identified as female or non-binary, 27% of presenters were Black, Indigenous, and People of Color (BIPOC), and 23% of presenters resided outside the United States.

Thriving in the ‘New Normal’

Over the course of the one-day event, attendees heard from technology experts across the community, including the following keynote headliners:

To replay LiveWorx keynotes, track spotlights, and more, access the LiveWorx 2020 Content Archive . Event replays will be available through Spring 2021.

Major Product Announcements Put Industrial Enterprise Technology at Precipice of Future

Coinciding with the momentum and excitement surrounding LiveWorx 20, PTC shared key product releases from its ThingWorx® IIoT Platform , and Windchill® PLM Software offerings; recent advancements following November’s acquisition of the Onshape® SaaS technology ; and the launch of the new Factory Insights as a Service product in collaboration with sponsors Rockwell Automation and Microsoft.

Alongside this year’s Title Sponsor, Analog Devices, 11 companies supported LiveWorx 20 including Pinnacle Sponsors Ansys, AT&T Business, Ericsson, EY, and Transition Technologies; and Premier Sponsors Archer Grey, Deloitte, EPLAN, Hewlett Packard Enterprise, and Kalypso.

About PTC (NASDAQ: PTC)

PTC enables global manufacturers to realize double-digit impact with software solutions that enable them to accelerate product and service innovation, improve operational efficiency, and increase workforce productivity. In combination with an extensive partner network, PTC provides customers flexibility in how its technology can be deployed to drive digital transformation – on premises, in the cloud, or via its pure SaaS platform. At PTC, we don’t just imagine a better world, we enable it.

PTC.com @PTC Blogs

PTC, LiveWorx, ThingWorx, Windchill, Onshape, and the PTC logo are trademarks or registered trademarks of PTC Inc. and/or its subsidiaries in the United States and other countries.

Link:

ClickThru

Social Media:

https://www.facebook.com/liveworxevent

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye